Advertisement
Collaboration › Details
Immatics–Leucadia: investor conference, 202209 supply service Immatics at Jefferies Cell and Genetic Medicine Summit 2022
Period | 2022-09-29 � 2022-09-30 | |
Region | New York, NY | |
Country | United States (USA) | |
Partner, 1st | Immatics N.V. (Nasdaq: IMTX) | |
Partner, 2nd | Jefferies LLC | |
Group | Leucadia (Group) | |
Source | Immatics N.V.. (8/9/22). "Press Release: Immatics Announces Second Quarter 2022 Financial Results and Business Update". Tübingen & Houston, TX. | |
Record changed: 2022-09-05 |
Advertisement
More documents for Immatics (Group)
- [1] Immatics N.V.. (10/10/24). "Press Release: Immatics Announces Updated Phase 1b Clinical Data on ACTengine IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial". Houston, TX & Tübingen....
- [2] Immatics N.V.. (10/10/24). "Press Release: Immatics Announces Proposed $150 Million Public Offering". Houston, TX & Tübingen....
- [3] Immatics N.V.. (7/31/24). "Press Release: Immatics Appoints Alise Reicin to Board of Directors". Houston, TX & Tübingen....
- [4] Immatics N.V.. (10/24/23). "Press Release: Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy". Houston, TX & Tübingen....
- [5] Immatics N.V.. (9/11/23). "Press Release: Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics". Cambridge, MA & Tübingen....
- [6] Immatics N.V.. (7/24/23). "Press Release: Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb". Tübingen & Houston, TX....
- [7] MicrofluidX Ltd.. (5/2/23). "Press Release: MicrofluidX and Immatics Working Together on Automated End-to-End Bioprocessing for TCR-T Therapies". Stevenage & Houston, TX....
- [8] AiCuris Anti-infective Cures AG. (9/1/22). "Press Release: AiCuris Appoints Experienced Business Leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer". Wuppertal....
- [9] Immatics N.V.. (8/23/22). "Press Release: Immatics Announces First Cancer Patient Treated with Second-generation ACTengine TCR-T Candidate IMA203CD8 Targeting PRAME". Houston, TX & Tübingen....
- [10] Immatics N.V.. (8/9/22). "Press Release: Immatics Announces Second Quarter 2022 Financial Results and Business Update". Tübingen & Houston, TX....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top